A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous revascularization

Journal of Vascular Surgery

Volumn 63, Issue 1, 2016, Pages 133-141.e1

  El Sayed, Hosam ^a   Kerensky, Richard ^b   Stecher, Michael ^c   Mohanty, Prasant ^c   Davies, Mark ^d  

^a OHIO STATE UNIVERSITY   (United States)

^b Archbold Medical Center   (United States)

^c Regulatory Division   (United States)

^d UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; INTERLEUKIN 1ALPHA; UNCLASSIFIED DRUG; XILONIX; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVERSE OUTCOME; ANGIOPLASTY; ARTICLE; ATHERECTOMY; CARDIOVASCULAR DISEASE; CLAUDICATION; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GROIN HEMATOMA; HUMAN; INCIDENCE; LEG REVASCULARIZATION; MALE; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; RISK ASSESSMENT; SUPERFICIAL FEMORAL ARTERY RESTENOSIS; VASCULAR PATENCY; ADVERSE EFFECTS; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG EFFECTS; FEMORAL ARTERY; HYPERPLASIA; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; NEOINTIMA; PATHOLOGY; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; PROCEDURES; RECURRENT DISEASE; SECONDARY PREVENTION; STENOSIS, OCCLUSION AND OBSTRUCTION; SUBCUTANEOUS DRUG ADMINISTRATION; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

AGED; ANGIOPLASTY; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CONSTRICTION, PATHOLOGIC; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEMORAL ARTERY; HUMANS; HYPERPLASIA; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NEOINTIMA; PERIPHERAL ARTERIAL DISEASE; RECURRENCE; SECONDARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VASCULAR PATENCY;

EID: 84955716787     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2015.08.069     Document Type: Article

References (21)

1. N. Shammas Epidemiology, classification, and modifiable risk factors of peripheral arterial disease Vasc Health Risk Manag 3 2007 229 234
2. A.T. Hirsch, Z.J. Haskal, and N.R. Hertzer ACC/AHA guidelines for the management of peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation J Am Coll Cardiol 47 2006 1239 1312
3. W.S. Aronow Peripheral arterial disease of the lower extremities Arch Med Sci 8 2012 375 388
4. J.A. Dormandy, and B. Rutherford Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC) J Vasc Surg 31 2000 S1 296
5. K.W. Johnston Femoral and popliteal arteries: reanalysis of results of balloon angioplasty Radiology 183 1992 767 771
6. E. Minar, B. Pokrajac, T. Maca, R. Ahmadi, C. Fellner, M. Mittlböck, and et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study Circulation 102 2000 2694 2699
7. O. Schlager, P. Dick, S. Sabeti, J. Amighi, W. Mlekusch, E. Minar, and et al. Long-segment SFA stenting - the dark sides: in-stent restenosis, clinical deterioration, and stent fractures J Endovasc Ther 12 2005 676 684
8. D. Scheinert, S. Duda, T. Zeller, H. Krankenberg, J. Ricke, M. Bosiers, and et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty JACC Cardiovasc Interv 7 2014 10 19
9. G.W. Stone, J.W. Moses, S.G. Ellis, J. Schofer, K.D. Dawkins, M.C. Morice, and et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 356 2007 998 1008
10. B. Lagerqvist, S.K. James, U. Stenestrand, J. Lindbäck, T. Nilsson, and L. Wallentin Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden N Engl J Med 356 2007 1009 1019
11. Y. Kamari, A. Shaish, S. Shemesh, E. Vax, I. Grosskopf, S. Dotan, and et al. Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-E-deficient mice lacking bone marrow-derived interleukin-1α Biochem Biophys Res Commun 405 2011 197 203
12. T. Waehre, A. Yndestad, C. Smith, T. Haug, S.H. Tunheim, L. Gullestad, and et al. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors Circulation 109 2004 1966 1972
13. C.F. Moyer, D. Sajuthi, H. Tulli, and J.K. Williams Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis Am J Pathol 138 1991 951 960
14. 2-macroglobulin, neutrophil elastase, and interleukin-1α differs in early-stage and late-stage atherosclerotic lesions in the arteries of the circle of Willis Acta Neuropathol 113 2007 33 43
15. K. Schultz, V. Murthy, J.B. Tatro, and D. Beasley Endogenous interleukin-1α promotes a proliferative and proinflammatory phenotype in human vascular smooth muscle cells Am J Physiol Heart Circ Physiol 292 2007 H2927 H2934
16. D. Beasley, and A. Cooper Constitutive expression of interleukin-1α precursor promotes human vascular smooth muscle cell proliferation Am J Physiol Heart Circ Physiol 276 1999 H901 H912
17. J. Chamberlain, M. Wheatcroft, N. Arnold, H. Lupton, D.C. Crossman, J. Gunn, and et al. A novel mouse model of in situ stenting Cardiovasc Res 85 2010 38 44
18. K. Isoda, M. Shiigai, N. Ishigami, T. Matsuki, R. Horai, K. Nishikawa, and et al. Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury Circulation 108 2003 516 518
19. A.C. Morton, N.D. Arnold, J. Gunn, R. Varcoe, S.E. Francis, S.K. Dower, and et al. Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary artery model Cardiovasc Res 68 2005 493 501
20. P. Garrone, O. Djossou, F. Fossiez, J. Reyes, S. Ait-Yahia, C. Maat, and et al. Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1α specific inhibitor Mol Immunol 33 1996 649 658
21. K.M. Coleman, J.E. Gudjonsson, and M. Stecher Open-label trial of MABp1, a true human monoclonal antibody targeting interleukin 1α, for the treatment of psoriasis JAMA Dermatol 151 2015 555 556